Literature DB >> 28794041

Interferon-Inducible CD169/Siglec1 Attenuates Anti-HIV-1 Effects of Alpha Interferon.

Hisashi Akiyama1, Nora-Guadalupe Pina Ramirez1, Gregory Gibson2, Christopher Kline3, Simon Watkins2, Zandrea Ambrose3, Suryaram Gummuluru4.   

Abstract

A hallmark of human immunodeficiency virus type 1 (HIV-1) infection in vivo is chronic immune activation concomitant with type I interferon (IFN) production. Although type I IFN induces an antiviral state in many cell types, HIV-1 can replicate in vivo via mechanisms that have remained unclear. We have recently identified a type I IFN-inducible protein, CD169, as the HIV-1 attachment factor on dendritic cells (DCs) that can mediate robust infection of CD4+ T cells in trans Since CD169 expression on macrophages is also induced by type I IFN, we hypothesized that type I IFN-inducible CD169 could facilitate productive HIV-1 infection in myeloid cells in cis and CD4+ T cells in trans and thus offset antiviral effects of type I IFN. In support of this hypothesis, infection of HIV-1 or murine leukemia virus Env (MLV-Env)-pseudotyped HIV-1 particles was enhanced in IFN-α-treated THP-1 monocytoid cells, and this enhancement was primarily dependent on CD169-mediated enhancement at the virus entry step, a phenomenon phenocopied in HIV-1 infections of IFN-α-treated primary monocyte-derived macrophages (MDMs). Furthermore, expression of CD169, a marker of type I IFN-induced immune activation in vivo, was enhanced in lymph nodes from pigtailed macaques infected with simian immunodeficiency virus (SIV) carrying HIV-1 reverse transcriptase (RT-SHIV), compared to uninfected macaques, and interestingly, there was extensive colocalization of p27gag and CD169, suggesting productive infection of CD169+ myeloid cells in vivo While cell-free HIV-1 infection of IFN-α-treated CD4+ T cells was robustly decreased, initiation of infection in trans via coculture with CD169+ IFN-α-treated DCs restored infection, suggesting that HIV-1 exploits CD169 in cis and in trans to attenuate a type I IFN-induced antiviral state.IMPORTANCE HIV-1 infection in humans causes immune activation characterized by elevated levels of proinflammatory cytokines, including type I interferons (IFN). Although type I IFN induces an antiviral state in many cell types in vitro, HIV-1 can replicate in vivo via mechanisms that have remained unclear. In this study, we tested the hypothesis that CD169, a type I IFN-inducible HIV-1 attachment factor, offsets antiviral effects of type I IFN. Infection of HIV-1 was rescued in IFN-α-treated myeloid cells via upregulation of CD169 and a subsequent increase in CD169-dependent virus entry. Furthermore, extensive colocalization of viral Gag and CD169 was observed in lymph nodes of infected pigtailed macaques, suggesting productive infection of CD169+ cells in vivo Treatment of dendritic cell (DC)-T cell cocultures with IFN-α upregulated CD169 expression on DCs and rescued HIV-1 infection of CD4+ T cells in trans, suggesting that HIV-1 exploits CD169 to attenuate type I IFN-induced restrictions.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  CD169; HIV; type I IFN; virus entry; virus evasion

Mesh:

Substances:

Year:  2017        PMID: 28794041      PMCID: PMC5640826          DOI: 10.1128/JVI.00972-17

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   6.549


  104 in total

1.  Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection.

Authors:  Gilad Doitsh; Nicole L K Galloway; Xin Geng; Zhiyuan Yang; Kathryn M Monroe; Orlando Zepeda; Peter W Hunt; Hiroyu Hatano; Stefanie Sowinski; Isa Muñoz-Arias; Warner C Greene
Journal:  Nature       Date:  2014-01-23       Impact factor: 49.962

2.  Characterization of the alpha interferon-induced postentry block to HIV-1 infection in primary human macrophages and T cells.

Authors:  Caroline Goujon; Michael H Malim
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

3.  Blockade of chronic type I interferon signaling to control persistent LCMV infection.

Authors:  Elizabeth B Wilson; Douglas H Yamada; Heidi Elsaesser; Jonathan Herskovitz; Jane Deng; Genhong Cheng; Bruce J Aronow; Christopher L Karp; David G Brooks
Journal:  Science       Date:  2013-04-12       Impact factor: 47.728

4.  Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response.

Authors:  Béatrice Jacquelin; Véronique Mayau; Brice Targat; Anne-Sophie Liovat; Désirée Kunkel; Gaël Petitjean; Marie-Agnès Dillies; Pierre Roques; Cécile Butor; Guido Silvestri; Luis D Giavedoni; Pierre Lebon; Françoise Barré-Sinoussi; Arndt Benecke; Michaela C Müller-Trutwin
Journal:  J Clin Invest       Date:  2009-12       Impact factor: 14.808

5.  Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus.

Authors:  Robert Biesen; Cemal Demir; Fidan Barkhudarova; Joachim R Grün; Marta Steinbrich-Zöllner; Marina Backhaus; Thomas Häupl; Martin Rudwaleit; Gabriela Riemekasten; Andreas Radbruch; Falk Hiepe; Gerd-Rüdiger Burmester; Andreas Grützkau
Journal:  Arthritis Rheum       Date:  2008-04

6.  Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.

Authors:  Stuart J D Neil; Trinity Zang; Paul D Bieniasz
Journal:  Nature       Date:  2008-01-16       Impact factor: 49.962

7.  Damaged intestinal epithelial integrity linked to microbial translocation in pathogenic simian immunodeficiency virus infections.

Authors:  Jacob D Estes; Levelle D Harris; Nichole R Klatt; Brian Tabb; Stefania Pittaluga; Mirko Paiardini; G Robin Barclay; Jeremy Smedley; Rhonda Pung; Kenneth M Oliveira; Vanessa M Hirsch; Guido Silvestri; Daniel C Douek; Christopher J Miller; Ashley T Haase; Jeffrey Lifson; Jason M Brenchley
Journal:  PLoS Pathog       Date:  2010-08-19       Impact factor: 6.823

8.  Virus particle release from glycosphingolipid-enriched microdomains is essential for dendritic cell-mediated capture and transfer of HIV-1 and henipavirus.

Authors:  Hisashi Akiyama; Caitlin Miller; Hiren V Patel; Steven C Hatch; Jacob Archer; Nora-Guadalupe P Ramirez; Suryaram Gummuluru
Journal:  J Virol       Date:  2014-05-28       Impact factor: 5.103

9.  Evolution of the HIV-1 env gene in the Rag2-/- gammaC-/- humanized mouse model.

Authors:  William L Ince; Liguo Zhang; Qi Jiang; Kathryn Arrildt; Lishan Su; Ronald Swanstrom
Journal:  J Virol       Date:  2009-12-30       Impact factor: 5.103

10.  IFITM3 inhibits influenza A virus infection by preventing cytosolic entry.

Authors:  Eric M Feeley; Jennifer S Sims; Sinu P John; Christopher R Chin; Thomas Pertel; Li-Mei Chen; Gaurav D Gaiha; Bethany J Ryan; Ruben O Donis; Stephen J Elledge; Abraham L Brass
Journal:  PLoS Pathog       Date:  2011-10-27       Impact factor: 6.823

View more
  23 in total

1.  LYAR Suppresses Beta Interferon Induction by Targeting Phosphorylated Interferon Regulatory Factor 3.

Authors:  Cha Yang; Xiaokun Liu; Tailang Cheng; Rong Xiao; Qingxia Gao; Fan Ming; Meilin Jin; Huanchun Chen; Hongbo Zhou
Journal:  J Virol       Date:  2019-10-15       Impact factor: 5.103

2.  A virus-packageable CRISPR screen identifies host factors mediating interferon inhibition of HIV.

Authors:  Molly OhAinle; Louisa Helms; Jolien Vermeire; Ferdinand Roesch; Daryl Humes; Ryan Basom; Jeffrey J Delrow; Julie Overbaugh; Michael Emerman
Journal:  Elife       Date:  2018-12-06       Impact factor: 8.140

3.  Virus-Mimicking Polymer Nanoparticles Targeting CD169+ Macrophages as Long-Acting Nanocarriers for Combination Antiretrovirals.

Authors:  Behnaz Eshaghi; Josiane Fofana; Sarah B Nodder; Suryaram Gummuluru; Björn M Reinhard
Journal:  ACS Appl Mater Interfaces       Date:  2022-01-07       Impact factor: 10.383

4.  Blood monocyte-derived CD169+ macrophages contribute to antitumor immunity against glioblastoma.

Authors:  Hyun-Jin Kim; Jang Hyun Park; Hyeon Cheol Kim; Chae Won Kim; In Kang; Heung Kyu Lee
Journal:  Nat Commun       Date:  2022-10-20       Impact factor: 17.694

5.  Membrane-wrapped nanoparticles probe divergent roles of GM3 and phosphatidylserine in lipid-mediated viral entry pathways.

Authors:  Fangda Xu; Asanga Bandara; Hisashi Akiyama; Behnaz Eshaghi; David Stelter; Tom Keyes; John E Straub; Suryaram Gummuluru; Björn M Reinhard
Journal:  Proc Natl Acad Sci U S A       Date:  2018-09-06       Impact factor: 12.779

Review 6.  Gut Innate Immunity and HIV Pathogenesis.

Authors:  Stephanie M Dillon; Cara C Wilson
Journal:  Curr HIV/AIDS Rep       Date:  2021-03-09       Impact factor: 5.495

7.  Safety, Immune, and Antiviral Effects of Pegylated Interferon Alpha 2b Administration in Antiretroviral Therapy-Suppressed Individuals: Results of Pilot Clinical Trial.

Authors:  Emmanouil Papasavvas; Livio Azzoni; Amélie Pagliuzza; Mohamed Abdel-Mohsen; Brian N Ross; Matthew Fair; Bonnie J Howell; Daria J Hazuda; Nicolas Chomont; Qingsheng Li; Karam Mounzer; Jay R Kostman; Pablo Tebas; Luis J Montaner
Journal:  AIDS Res Hum Retroviruses       Date:  2021-01-29       Impact factor: 1.723

8.  Interferon Alpha Favors Macrophage Infection by Visceral Leishmania Species Through Upregulation of Sialoadhesin Expression.

Authors:  Lieselotte Van Bockstal; Dimitri Bulté; Magali Van den Kerkhof; Laura Dirkx; Dorien Mabille; Sarah Hendrickx; Peter Delputte; Louis Maes; Guy Caljon
Journal:  Front Immunol       Date:  2020-06-09       Impact factor: 7.561

9.  Myeloid cell interferon responses correlate with clearance of SARS-CoV-2.

Authors:  Dhiraj Singh; Ekaterina Aladyeva; Shibali Das; Bindu Singh; Ekaterina Esaulova; Amanda Swain; Mushtaq Ahmed; Journey Cole; Chivonne Moodley; Smriti Mehra; Larry Schlesinger; Maxim Artyomov; Shabaana Khader; Deepak Kaushal
Journal:  Res Sq       Date:  2021-07-15

Review 10.  Type I Interferon Responses by HIV-1 Infection: Association with Disease Progression and Control.

Authors:  Andrew Soper; Izumi Kimura; Shumpei Nagaoka; Yoriyuki Konno; Keisuke Yamamoto; Yoshio Koyanagi; Kei Sato
Journal:  Front Immunol       Date:  2018-01-15       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.